During the past decade, Minneapolis Heart Institute Foundation conducted 61 clinical trials. In the 10-year time frame, 61 clinical trials started and 28 clinical trials were completed, i.e. on average, 45.9% percent of trials that started reached the finish line to date. In the past 5 years, 30 clinical trials started and 11 clinical trials were completed. i.e. 36.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Minneapolis Heart Institute Foundation" #1 sponsor was "Minneapolis Heart Institute Foundation" with 11 trials, followed by "Medtronic Cardiac Rhythm and Heart Failure" with 8 trials sponsored, "Edwards Lifesciences" with 6 trials sponsored, "The University of Texas Health Science Center, Houston" with 6 trials sponsored and "Ancora Heart, Inc." with 6 trials sponsored. Other sponsors include 56 different institutions and companies that sponsored additional 53 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Minneapolis Heart Institute Foundation" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 11 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Medtronic" with 2 trials as a collaborator, "Abbott Medical Devices" with 1 trials as a collaborator and "Aldagen" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Minneapolis Heart Institute Foundation" are "Heart Failure" (13 trials), "Coronary Artery Disease" (10 trials), "Cardiovascular Diseases" (6 trials), "Congestive Heart Failure" (4 trials) and "Myocardial Infarction" (4 trials). Many other conditions were trialed in "Minneapolis Heart Institute Foundation" in a lesser frequency.

Most popular intervention types in "Minneapolis Heart Institute Foundation" are "Device" (39 trials), "Drug" (29 trials), "Biological" (13 trials), "Procedure" (10 trials) and "Other" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Adult stem cells" (3 trials), "Bococizumab (PF-04950615;RN316)" (2 trials), "Micra Pacemaker Implant" (2 trials) and "Sham Procedure" (2 trials). Other intervention names were less common.

The vast majority of trials in "Minneapolis Heart Institute Foundation" are 95 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Minneapolis Heart Institute Foundation". 2 are not yet recruiting, 18 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 44 completed trials in Minneapolis Heart Institute Foundation, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Minneapolis Heart Institute Foundation, 7 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 33 trials that are defined as “Not Applicable".